|
Adjunct Professor, Faculty of Medicine, McGill University
Dr. Miller's Publications Indexed on PubMed
Dr. Mark Miller graduated from medical school at McGill University in 1982. He went on to do specialty training in Montreal in the fields of internal medicine, infectious diseases, and medical microbiology, for which he received Royal College and Quebec certification in 1988. He received a Master’s degree in Epidemiology and Biostatistics from McGill in 1990. His Master’s research focused on the genetic factors which determine resistance to tuberculosis among aboriginal people in Alberta.He was a staff microbiologist and infectious disease specialist at the Montreal General Hospital for five years before moving to the Jewish General Hospital in 1993, where he became the Chair of Infection Prevention and Control, Chief of Microbiology, and Head of the Division of Infectious Diseases. Subsequently, the bulk of his research has been in the epidemiology, prevention, and treatment of nosocomial (i.e. hospital-acquired) infections. He has described the rapid emergence of mupirocin resistance among methicillin-resistant Staphylococcus aureus (MRSA) during use of this antibiotic in outbreak control, chaired the cross-Canada group studying the morbidity, health effects, and death rate from hospital-acquired C. difficile-associated diarrhea (CDAD), and headed the Canadian team which surveyed the re-use of single-use medical devices. He is currently concentrating on four aspects of CDAD research: 1) annual Canadian surveillance studies of healthcare-associated CDAD, which include genetic studies of the organism; 2) a case-control study of the utility of IVIG in the therapy of severe CDAD; 3) a study of household transmission of C. difficile; and 4) novel therapeutic agents for the treatment of CDAD.He was a member of the provincial committee, created by the Quebec Hospital Association and the Association of Microbiologists of Quebec, which established guidelines for the re-use of single-use medical devices (2004). In addition, he was also a member of the committee formed by the Order of Physicians of Quebec which wrote the guidelines applicable to physicians infected with blood-borne diseases (2004).Since 1996, he has been Chair of the Infection Control Working Group of the McGill University Teaching Hospital Council (MUTHC) in an effort to harmonize infection prevention and control practices in the Faculty of Medicine and in all McGill affiliated health institutions.He has co-authored more than 110 peer-reviewed articles and over 130 abstract presentations and continues to publish studies, mainly in the field of healthcare-associated infections.He is a past President of the Association of Medical Microbiology and Infectious Disease of Canada (AMMI-Canada), the professional society of over 500 Canadian physicians involved in prevention, diagnosis, treatment, and research in the vast field of infectious diseases.Since October 2012, Dr. Miller has been Chief Medical Officer at bioMérieux (France) and a member of the company’s Executive Management Committee. Multiple roles within bioMerieux, contained within the Office of Medical and Scientific Affairs, include: the head of the Global Medical Affairs group, the Medical Diagnostics Discovery Department, the Clinical Affairs and Regulatory Affairs groups and the Companion Diagnostics activities. His major concentration is on demonstrating the medical value and health benefits of the company’s diagnostic tools, as well as medical education, focusing on improving outcomes for patients, healthcare institutions and the entire medical system.
Currently an Adjunct Professor with McGill University’s Faculty of Medicine, he continues to undertake part-time research on healthcare-associated infections at McGill, and continues to publish his findings.
Major Research Activities
Dr. Miller is currently concentrating on five aspects of C. difficile infection (CDI) research: 1) annual Canadian surveillance studies of healthcare-associated CDI; 2) a study of the household transmission of C. difficile; 3) serologic and immune markers related to CDI; 4) novel therapeutic agents for the prevention and treatment of CDI; and 5) the fecal microbiome following stool transplantation for recurrent CDI.
Recent Publications
Miller M, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, Kean Y and Sears P. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infectious Diseases 2013;13:148-54.
Haraoui L-P, Levesque S, Lefebvre B, Blanchette R, Tomkinson M, Matasejec L, Mulvey MR, Miller MA. Polyclonal Outbreak of KPC-3-producing Enterobacter cloacae at a Single Hospital in Montréal, Canada. JCM 2013;51:2406-8.
Chong PM, Lynch T, McCorrister S, Kibsey P, Miller M, Gravel D, Westmacott GR, Mulvey MR, and the Canadian Nosocomial Infection Surveillance Program (CNISP). Proteomic analysis of a NAP1 Clostridium difficile clinical isolate resistant to metronidazole. PLOS ONE 2014;9:e82622.
Vincent C, Miller MA, Edens TJ, Mehrotra S, Dewar K, Manges AR. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome 2016;4:12-22. |